ATRA
Price
$1.65
Change
-$0.15 (-8.38%)
Updated
Sep 25, 1:43 PM EST
43 days until earnings call
CHRS
Price
$4.07
Change
-$0.39 (-8.74%)
Updated
Sep 25, 2:31 PM EST
45 days until earnings call

ATRA vs CHRS ᐉ Comparison: Which is Better to Invest?

Header iconATRA vs CHRS Comparison
Open Charts ATRA vs CHRSBanner chart's image
Atara Biotherapeutics
Price$1.65
Change-$0.15 (-8.38%)
Volume$5K
CapitalizationN/A
Coherus BioSciences
Price$4.07
Change-$0.39 (-8.74%)
Volume$500
CapitalizationN/A
View a ticker or compare two or three
ATRA vs CHRS Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
ATRA vs. CHRS commentary
Sep 25, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATRA is a Hold and CHRS is a Hold.

COMPARISON
Comparison
Sep 25, 2023
Stock price -- (ATRA: $1.79 vs. CHRS: $4.46)
Brand notoriety: ATRA and CHRS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATRA: 109% vs. CHRS: 96%
Market capitalization -- ATRA: $180.97M vs. CHRS: $474.5M
ATRA [@Biotechnology] is valued at $180.97M. CHRS’s [@Biotechnology] market capitalization is $474.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $410.28B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATRA’s FA Score shows that 0 FA rating(s) are green whileCHRS’s FA Score has 0 green FA rating(s).

  • ATRA’s FA Score: 0 green, 5 red.
  • CHRS’s FA Score: 0 green, 5 red.
According to our system of comparison, CHRS is a better buy in the long-term than ATRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATRA’s TA Score shows that 6 TA indicator(s) are bullish while CHRS’s TA Score has 3 bullish TA indicator(s).

  • ATRA’s TA Score: 6 bullish, 3 bearish.
  • CHRS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ATRA is a better buy in the short-term than CHRS.

Price Growth

ATRA (@Biotechnology) experienced а +16.99% price change this week, while CHRS (@Biotechnology) price change was -9.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.16%. For the same industry, the average monthly price growth was +21.79%, and the average quarterly price growth was +33.92%.

Reported Earning Dates

ATRA is expected to report earnings on Nov 07, 2023.

CHRS is expected to report earnings on Nov 09, 2023.

Industries' Descriptions

@Biotechnology (-3.16% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ATRA with price predictions.
OPEN
A.I.dvisor published
a Summary for CHRS with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CHRS($474M) has a higher market cap than ATRA($181M). CHRS (-43.687) and ATRA (-45.427) have similar YTD gains . CHRS has higher annual earnings (EBITDA): -223.66M vs. ATRA (-349.11M). ATRA has more cash in the bank: 154M vs. CHRS (145M). ATRA has less debt than CHRS: ATRA (64.7M) vs CHRS (479M). CHRS has higher revenues than ATRA: CHRS (182M) vs ATRA (6.86M).
ATRACHRSATRA / CHRS
Capitalization181M474M38%
EBITDA-349.11M-223.66M156%
Gain YTD-45.427-43.687104%
P/E RatioN/AN/A-
Revenue6.86M182M4%
Total Cash154M145M106%
Total Debt64.7M479M14%
FUNDAMENTALS RATINGS
ATRA vs CHRS: Fundamental Ratings
ATRA
CHRS
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
90
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
5963
P/E GROWTH RATING
1..100
10059
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATRA's Valuation (80) in the Biotechnology industry is in the same range as CHRS (90). This means that ATRA’s stock grew similarly to CHRS’s over the last 12 months.

ATRA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CHRS (100). This means that ATRA’s stock grew similarly to CHRS’s over the last 12 months.

ATRA's SMR Rating (99) in the Biotechnology industry is in the same range as CHRS (100). This means that ATRA’s stock grew similarly to CHRS’s over the last 12 months.

ATRA's Price Growth Rating (59) in the Biotechnology industry is in the same range as CHRS (63). This means that ATRA’s stock grew similarly to CHRS’s over the last 12 months.

CHRS's P/E Growth Rating (59) in the Biotechnology industry is somewhat better than the same rating for ATRA (100). This means that CHRS’s stock grew somewhat faster than ATRA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATRACHRS
RSI
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
82%
Momentum
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
89%
MACD
ODDS (%)
Bullish Trend 4 days ago
75%
Bearish Trend 4 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
82%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 11 days ago
78%
Declines
ODDS (%)
Bearish Trend 13 days ago
89%
Bearish Trend 5 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
84%
Bullish Trend 4 days ago
76%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGRUX97.310.27
+0.28%
Baron Growth R6
ADVJX12.07N/A
N/A
Vaughan Nelson International Sm Cap Inv
FRSLX20.62-0.02
-0.10%
Nuveen Mid Cap Growth Opps A
CIHEX14.24-0.03
-0.21%
Calamos Hedged Equity I
BRMIX12.42-0.03
-0.24%
iShares Russell Mid-Cap Index Instl

ATRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATRA has been loosely correlated with EDIT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ATRA jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATRA
1D Price
Change %
ATRA100%
+0.56%
EDIT - ATRA
52%
Loosely correlated
-1.88%
NTLA - ATRA
52%
Loosely correlated
-3.40%
CHRS - ATRA
52%
Loosely correlated
+7.73%
BEAM - ATRA
50%
Loosely correlated
-4.81%
AGEN - ATRA
49%
Loosely correlated
-0.84%
More

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with ATRA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then ATRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
+7.73%
ATRA - CHRS
52%
Loosely correlated
+0.56%
CYTK - CHRS
47%
Loosely correlated
-0.93%
ENTA - CHRS
46%
Loosely correlated
+0.68%
MDGL - CHRS
43%
Loosely correlated
-3.87%
LXRX - CHRS
40%
Loosely correlated
-5.31%
More